Hormone Therapy News

SAN ANTONIO — Imlunestrant alone or as part of combination therapy extended PFS for certain patients with advanced breast cancer resistant to hormone therapy, according to study results presented at San Antonio Breast Cancer Symposium.

Cardiovascular disease risks vary depending on the type of menopausal hormone therapy combinations and administration methods used, according to a nationwide trial published in The BMJ.

Short-term exposure to hormone therapy started within 3 years of menopause was not associated with long-term cognitive impairment or benefit, according to data from the KEEPS Continuation study.

Patients using testosterone replacement therapy for at least 3 months may have an increased risk for ACL injuries, according to recently published data.

DENVER — Bilateral oophorectomy was common during gender-affirming hysterectomy and associated with younger age, prior testosterone use and male identity, according to study results presented at the ASRM Scientific Congress & Expo.

DENVER — Exposure to testosterone therapy did not impact outcomes related to egg freezing for transgender men who sought fertility preservation treatment, researchers reported.

Prior testosterone exposure did not impact oocyte cryopreservation outcomes among transgender and gender-diverse adolescents and young adults, according to a research letter published in Obstetrics & Gynecology.

Hormone therapy use markedly declined among postmenopausal women of all ages, races and ethnicities in the U.S. during the past 2 decades, according to findings published in JAMA Health Forum.

CHICAGO — In this Healio video exclusive, Pauline M. Maki, PhD, provides three takeaways from her talk on cognition and hormone therapy during menopause at the Annual Meeting of The Menopause Society.